

Harrell R. MS, Kwon A., Karhade M. MD PhD, Robert N. MD, Wu N. MD, Heller B. MD, Alwardt S. PhD, Moore L., and Smith H. PhD MPH
The US Oncology Network (USON), US Oncology Research, Ontada (a McKesson Corporation business)

Background

- To date, 754K deaths have been attributed to COVID-19 in the US
- FDA granted Emergency Use Authorization (EUA) for the 1st COVID-19 vaccine on 12/11/20
- Study marks review of 10 months post EUA of COVID-19 vaccines
- US Oncology (USON) treats more than 1.2 million patients annually

Objective

- Explore vaccination rates among cancer patients on active chemo

Methods

- Patients ≥ 18 years, with a cancer diagnosis at a USON clinic, two or more office visits after 1/1/21 and chemo on or after 12/1/20
- Data was retrospectively extracted from iKnowMed (iKM) database, which is Ontada’s oncology-specific electronic health record (EHR)
- Patients in “Vaccine Initiated” received their first dose, whereas those in “Vaccine Completed” are fully vaccinated (1 or 2 doses depending on manufacturer)
- Those in “Absence of Vaccination” had no record of vaccination

Table 1. Patient Demographics

	Absence of Vaccination n=35,077 (49%)	Any Vaccination n=36,788 (51%)
Age*		
Mean (Std dev)	66 (13)	68 (12)
Gender		
Female	19,502 (48%)	19,873 (52%)
Male	16,156 (47%)	16,915 (53%)
Disease Status*		
Metastatic Disease	24,588 (47%)	27,695 (53%)
Localized Disease	11,070 (49%)	11,681 (51%)

* Statistically significant, p < 0.0001

Data Overview

Figure 1. Vaccination by Race




Figure 2. Vaccination Cumulative Totals by Month




Table 2. Vaccinations by Manufacturers

	Pfizer N (%)	Moderna N (%)	Janssen N (%)	Astra-Zeneca N (%)
Patient Count (%)	18,805 (51%)	16,160 (44%)	1770 (5%)	53 (<1%)

Table 3. Top 5 Documented Reasons for Vaccine Exception

Note: N = number of all records with available reasons

Reason	N (%)
Reason not available	1,162 (64%)
Other/Not received due to other reason	456 (25%)
Not received due to patient objection	82 (4%)
Not received due to medical precaution/contraindication	60 (3%)

Results

- Statistically significant differences in vaccination rates observed across age (p<0.0001) and disease status (p<0.0001)
- 68% (25,176) of vaccinated patients were white
- 70% (25,676) of vaccinated patients were vaccinated in the first five months
- The rate of completing vaccines plateaus around June, while the rate of initiating vaccines continues to increase
- 49% (35,077) of patients lack COVID-19 vaccination data
- 3% (2,024) of patients had a documented vaccine exception

Limitations

- Vaccination responses are largely self-reported

Conclusion

- Active chemo cancer patients’ vaccination rates are lower than national reported vaccination rates (51% vs 68%)
- 21,821 (30%) of patients initiated vaccination without completion
- The majority of vaccinated USON cancer patients received Pfizer